Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO102-IO103 + Pembrolizumab in Resectable Melanoma and Head & Neck Cancer
NCT05280314Phase 2Recruiting
- Sponsor
- IO Biotech
- Start
- Dec 2023
- Primary completion
- Apr 2025
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 6
01
Overview
A Phase 2 trial of PD-L1/IDO peptide vaccine in melanoma, head and neck squamous cell carcinoma (HNSCC), sponsored by IO Biotech. Started Dec 2023; status: recruiting.
02
Drugs
PD-L1/IDO peptide vaccine
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05280314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05280314.